EnteroMedics Inc. (NASDAQ:RSLS) issued its quarterly earnings results on Tuesday. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.77), Bloomberg Earnings reports. EnteroMedics had a negative return on equity of 167.73% and a negative net margin of 4,399.48%.
EnteroMedics (NASDAQ:RSLS) traded down $0.05 during mid-day trading on Tuesday, hitting $1.65. 217,000 shares of the company were exchanged, compared to its average volume of 1,693,029. EnteroMedics has a 12-month low of $1.47 and a 12-month high of $30.41.
RSLS has been the topic of several research reports. Zacks Investment Research raised shares of EnteroMedics from a “hold” rating to a “strong-buy” rating and set a $2.25 price target on the stock in a research report on Wednesday, August 23rd. ValuEngine cut shares of EnteroMedics from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd.
ILLEGAL ACTIVITY WARNING: “EnteroMedics Inc. (RSLS) Posts Quarterly Earnings Results, Misses Expectations By $0.77 EPS” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/14/enteromedics-inc-rsls-posts-quarterly-earnings-results-misses-expectations-by-0-77-eps.html.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.